Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nasal Decongestants Monograph Amendment On Sinusitis Claims Planned

This article was originally published in The Tan Sheet

Executive Summary

FDA is targeting June for a proposed amendment to the cough/cold nasal decongestant monograph regarding sinusitis claims, according to the agency's recently published "unified agenda.
Advertisement

Related Content

FDA Proposes “Sinusitis” Exclusion From OTC Nasal Decongestant Monograph
FDA Proposes “Sinusitis” Exclusion From OTC Nasal Decongestant Monograph
FDA Proposes “Sinusitis” Exclusion From OTC Nasal Decongestant Monograph
HHS “Unified Agenda” Shows FDA Lagging On OTC Actions
HHS “Unified Agenda” Shows FDA Lagging On OTC Actions
FDA Analgesic Safety Campaign Launches; Label Warnings Still In Progress
Tylenol Sinus Severe Congestion Targets Consumers With Sinusitis
Tylenol Sinus Severe Congestion Targets Consumers With Sinusitis
Aspirin, NSAID GI Bleeding Language Could Replace Alcohol Warning
Phenylephrine Bitartrate GRAS/E Status Supported By Bayer Safety Data

Topics

Advertisement
UsernamePublicRestriction

Register

PS096380

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel